{
    "symbol": "PTE",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 17:08:14",
    "content": " Before we begin, I would like to remind everyone that today's discussion will include statements about the company's future expectations, plans and prospects, including but not limited to, statements about our financial resources, operations, our open IND and related clinical trials, and INDs and clinical trials for other SkinTE indications, which constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. For the three months period ended June 30, 2022, cash used in operating activities was $8.2 million, which includes $2.1 million of professional fees incurred in connection with our pursuit of a strategic transit action that did not materialize. Excluding these items, our base operating cash used in operating activities was $5 million or an average of $1.7 million per month, compared to $4.1 million of cash used in operating activities or an average of $1.4 million per month for the three month period ended June 30, 2021."
}